Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis

Ratziu Vlad; Bedossa Pierre; Francque Sven M.; Larrey Dominique; Aithal Guruprasad P.; Serfaty Lawrence; Voiculescu Mihai; Preotescu Liliana; Nevens Frederik; De Ledinghen Victor; Kirchner Gabriele I.; Trunecka Pavel; Ryder Stephen D.; Day Christopher P.; Takeda Jun; Traudtner Klaudia

首页> 外文期刊>Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association >Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis

【24h】

Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis

机译：缺乏PDE4抑制剂在1期和2级试验中的非酒精性脂肪性肝炎患者的试验的疗效

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUND & AIMS: ASP9831 is a phosphodiesterase-4 inhibitor developed to treat nonalcoholic steatohepatitis (NASH); it showed potent anti-inflammatory and antifibrotic effects in preclinical studies. We evaluated the efficacy and safety of ASP9831 in patients with NASH.

机译：背景和目的：ASP9831是一种开发的磷酸二酶-4抑制剂，以治疗非酒精性脂肪肝炎（NASH）; 它显示出临床前研究中有效的抗炎和抗纤维化效应。我们评估了ASP9831在纳什患者中的疗效和安全性。

著录项

来源
《Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association》 |2014年第10期|共12页
作者
Ratziu Vlad; Bedossa Pierre; Francque Sven M.; Larrey Dominique; Aithal Guruprasad P.; Serfaty Lawrence; Voiculescu Mihai; Preotescu Liliana; Nevens Frederik; De Ledinghen Victor; Kirchner Gabriele I.; Trunecka Pavel; Ryder Stephen D.; Day Christopher P.; Takeda Jun; Traudtner Klaudia;
展开▼
作者单位

Univ Paris 06 Hop La Pitie Salpetriere Assistance Publ Hop Paris INSERM UMR S 938 Paris France;

Univ Paris Diderot Hop Beaujon INSERM U773 Paris France;

Univ Antwerp Dept Gastroenterol &

Hepatol Univ Antwerp Hosp Fac Med &

Hlth Sci B-2020 Antwerp;

Hop St Eloi Dept Hepatogastroenterol &

Transplantat INSERM1040 IRB Montpellier France;

Nottingham Univ Hosp NHS Trust Natl Inst Hlth Res NIHR Biomed Res Unit Gastroint Nottingham;

Univ Paris 06 Hop St Antoine Assistance Publ Hop Paris Serv Hepatol INSERM UMR 938 Paris France;

Fundeni Clin Inst Dept Internal Med &

Nephrol Bucharest Romania;

Matei Bals Natl Inst Infect Dis Bucharest Romania;

Univ Hosp KU Leuven Dept Hepatol Leuven Belgium;

Hop Haut Leveque Serv Hepatogastro Enterol Pessac France;

Univ Hosp Regensburg Dept Internal Med 1 Regensburg Germany;

Inst Clin &

Expt Med IKEM Dept Hepatogastroenterol Prague Czech Republic;

Nottingham Univ Hosp NHS Trust Natl Inst Hlth Res NIHR Biomed Res Unit Gastroint Nottingham;

Newcastle Univ Inst Cellular Med Fac Med Sci Newcastle Upon Tyne NE1 7RU Tyne &

Wear England;

Astellas Pharma Inc Tokyo Japan;

Astellas Pharma Europe BV Leiden Netherlands;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词
Fatty Liver Disease; Therapeutic Targets; Treatment; PDE4;

机译：脂肪肝病;治疗目标;治疗;PDE4;

相似文献

外文文献
中文文献
专利

1. Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis [J] . Ratziu Vlad, Bedossa Pierre, Francque Sven M., Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association . 2014,第10期

机译：在非酒精性脂肪性肝炎患者的1期和2期试验中缺乏PDE4抑制剂的功效
2. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) [J] . Papp Kim, Reich Kristian, Leonardi Craig L., Journal of the American Academy of Dermatology . 2015,第1期

机译：口服磷酸二酯酶4（PDE4）抑制剂Apremilast在中度至重度斑块状牛皮癣患者中的应用：一项III期随机对照试验的结果（疗效和安全性试验，评估Apremilast对牛皮癣的影响[ESTEEM] 1）
3. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial [J] . Loomba Rohit, Lawitz Eric, Mantry Parvez S., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2018,第2期

机译：Ask1抑制剂Selonsertib在非酒精性脂肪型肝炎患者中：随机，第2期试验
4. A Deep Learning Approach for Classifying Nonalcoholic Steatohepatitis Patients from Nonalcoholic Fatty Liver Disease Patients Using Electronic Medical Records [C] . Pradyumna Byappanahalli Suresha, Yunlong Wang, Cao Xiao, Health Intelligence Workshop;Association for the Advancement of Artificial Intelligence Annual Conference . 2020

机译：使用电子医疗记录对非酒精性脂肪肝病患者的非酒精性脂肪性肝炎患者的深入学习方法
5. A Disease Progression Modeling Framework for Nonalcoholic Steatohepatitis Using Multiparametric Serial Magnetic Resonance Imaging and Elastography [D] . Deshpande, Eeshan. 2021

机译：利用多醇串串磁共振成像和弹性术治疗非酒精性脱脑肝炎的疾病进展框架
6. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized phase 2 trial [O] . Rohit Loomba, Eric Lawitz, Parvez S. Mantry, -1

机译：非酒精性脂肪性肝炎患者中ASK1抑制剂selonsertib的2期随机试验
7. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). [O] . Papp, Kim, Reich, Kristian, Leonardi, Craig L, 2015

机译：apremilast，一种口服磷酸二酯酶4（pDE4）抑制剂，用于中度至重度斑块状银屑病患者：III期随机对照试验的结果（评估apremilast在银屑病中的作用的功效和安全性试验[EsTEEm] 1）。
8. Effect of Metformin and Standard Therapy Versus Standard Therapy Alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial [R] . Shields, W. W., Thompson, K. E., Grice, G. A., 2009

机译：二甲双胍和标准治疗与标准治疗对胰岛素抵抗和非酒精性脂肪性肝炎（NasH）非糖尿病患者单独使用的影响：试验

Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis

摘要

著录项

相似文献

相关主题

期刊订阅